Form 4: Janux CMO William Go Receives Significant Equity Grants

Janux Therapeutics' Chief Medical Officer, William Go, was granted 44,000 restricted stock units and options for 154,000 shares.

Summary

• William Go, Chief Medical Officer of Janux Therapeutics, Inc. (JANX), received equity grants on February 2, 2026.
• The grants include 44,000 Restricted Stock Units (RSUs) and stock options for 154,000 shares of common stock.
• The RSUs vest in four equal annual installments, commencing on February 1, 2027.
• The stock options have an exercise price of $13.99 per share and expire on February 1, 2036.
• 25% of the stock options vest on February 26, 2027, with the remaining balance vesting in equal monthly installments over a three-year period thereafter.
• Following these transactions, William Go beneficially owns 44,000 shares of common stock (from RSUs) and 154,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the company's commitment to retaining and incentivizing key executive talent, aligning management's interests with long-term shareholder value, despite the potential for future dilution.

Positives

• Equity grants align the Chief Medical Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The significant number of shares and options granted indicates a commitment to retaining key executive talent within the company.

Negatives

• Future exercise of options and vesting of RSUs will result in potential dilution for existing shareholders.
• The grants represent a future compensation expense for the company, impacting financial statements over the vesting period.

Risks

• Potential dilution of existing shareholder value upon the vesting and exercise of the granted equity.
• The value of the compensation is tied to the company's stock performance, which is subject to market volatility, clinical trial outcomes, and broader operational risks inherent in the biotechnology sector.

Future Outlook

The vesting schedules for both the RSUs and stock options extend several years into the future, indicating a long-term incentive structure for the Chief Medical Officer, aligning future performance with compensation.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is a standard regulatory disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that equity grants, including Restricted Stock Units and stock options, are a standard and widely adopted practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is designed to attract, retain, and motivate key talent by linking their financial success directly to the company's long-term performance and shareholder value creation, especially critical in R&D-intensive sectors like biotech.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in the biotech sector typically include a mix of RSUs and stock options, similar to this grant.
• Comparable grants at early-to-mid stage biotech companies often range from tens of thousands to hundreds of thousands of shares/options, depending on company size, stage of development, and executive experience.
• The vesting schedule of 3-4 years for options and RSUs is also a common industry standard, aiming to ensure long-term commitment. For example, a CMO at a peer company like Mirati Therapeutics or Relay Therapeutics might receive similar grants upon joining or as part of annual compensation, with similar vesting structures designed to retain talent through critical clinical development phases.

Corporate Governance

Related Party Transactions

• Grant of 44,000 Restricted Stock Units to William Go, Chief Medical Officer.
• Grant of stock options for 154,000 shares to William Go, Chief Medical Officer.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of equity, but also benefit from aligned management incentives for long-term value creation.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs and overall compensation philosophy.

Next Steps

• First annual vesting installment of RSUs on February 1, 2027.
• Vesting of 25% of stock options on February 26, 2027.
• Subsequent monthly vesting of stock options over three years following the initial 25% vest.
• Subsequent annual vesting of RSUs over three more years.

Key Dates

Keywords

Janux Therapeutics, JANX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Chief Medical Officer, Executive Compensation, Beneficial Ownership